ERAP1 and melanoma: Consistently, Koumantou and colleagues demonstrated that pharmacological inhibition of ERAP1 in a melanoma cell line induced profound changes in both the quality and quantity of one half of the peptides presented, specifically increasing the presentation of peptides with high binding affinity for HLA class I molecules (74).